A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

What Was Tested

In this phase 1 trial, researchers set out to test Survodutide.

This study is open to healthy people between 18 and 65 years of age.

People can join the study if they have a body mass index between 27 and 39.9 kg/m2.

The purpose of this study is to test a new formulation of a medicine called survodutide.

It had two arms (groups): survodutide formulation A (reference treatment) (active comparator) and survodutide formulation B2 (test treatment) (experimental).

The registry classes the interventions as combination product.

Who Took Part

The registry lists 100 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Age of 18 to 65 years (inclusive). Body mass index (BMI) of 27.0 to 39.9 kg/m² (inclusive). Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Further inclusion criteria apply.

The full record lists 4 inclusion and 4 exclusion criteria; among the exclusions: any finding in the medical examination (including bp, pr or ecg) deviating from normal and assessed as clinically relevant by the investigator; any laboratory value outside the reference range that the investigator considers to be of clinical relevance.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Survodutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Survodutide group and the comparison group ran side by side rather than switching.

Being open-label, the Survodutide study did not mask who received what.

It started in 2025-11-05 with completion listed for 2026-07-28.

It ran at 2 sites in Germany (2).

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Survodutide in 100 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Survodutide compound page, all human trials.